subsidiary is sold to private investors, permanently separating the business from its German parent.ġ961: The first birth control pill is introduced by Schering in the European market.ġ 9702: The company gradually reenters the U.S. government takes control of all German properties in America, including Schering Corporation.ġ945: Schering begins to rebuild destroyed factories and recover from the loss of patents and naming rights.ġ952: Schering's U.S. We are committed to the principle of sustainable, future-oriented development.ġ851: Ernst Schering opens his pharmacy, Gruene Apotheke, in Berlin.ġ871: Ernst Schering's operations are incorporated as Chemische Fabrik auf Actien.ġ901: The company's operations expand into the area of electroplating.ġ918: Schering's American subsidiaries dissolve due to trading with the Enemy Act.ġ929: The company returns to the United States by founding Schering Corporation in New York.ġ932: The company merges with Oberkoks, a mining and chemical company, and adopts Schering AG as its name.ġ942: The U.S. Being a global player enables us to be aware of different market conditions and our customers' needs, since we are present in many locations: Schering AG has more than 130 subsidiaries worldwide. With its innovative products, Schering AG aims for leading positions in specialized markets worldwide. NAIC: 325412 Pharmaceutical Preparation Manufacturing Ticker Symbol: SCH (Germany), SHR (New York) Stock Exchanges: Basel Berlin Bremen Düsseldorf Frankfurt Geneva Hamburg Hanover London Munich New York Stuttgart Zurich Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).Sales: EUR 4.84 billion (US$4.31 billion) (2001) Current multiples include: - Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM) - Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. One of the most widely used quantitative methods is the market multiples method. In reality, business valuation is often a combination of these different approaches. Many methods can be used to value a company. The (current) company valuation of Bayer Schering Pharma AG is therefore way below its valuation average over the last five years. The N/A ratio of Bayer Schering Pharma AG is significantly lower than its historical 5-year average: N/A.
The company valuation of Bayer Schering Pharma AG according to these metrics is way below the market valuation of its sector. The N/A ratio of Bayer Schering Pharma AG is significantly lower than the average of its sector (Pharmaceuticals): 7.09.
The company valuation of Bayer Schering Pharma AG according to these metrics is way below the market valuation of its peer group. The N/A ratio of Bayer Schering Pharma AG is significantly lower than the median of its peer group: around 15.00. A company with a high N/A is considered to be overvalued a company with a low N/A is considered to be undervalued. This multiple is used to compare a company's market value with its earnings. P/E relates the current share price with the market expectations in terms of Earnings Per Share. The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). Market multiple valuation of Bayer Schering Pharma AG ( SCH | DEU)
0 kommentar(er)
